Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens AB, Leiser A, Mayer T, Chan N, Spencer K, Girda E, Malhotra J, Chan T, Subbiah V, Groisberg R.
Palmeri M, et al. Among authors: malhotra j.
ESMO Open. 2022 Feb;7(1):100336. doi: 10.1016/j.esmoop.2021.100336. Epub 2021 Dec 23.
ESMO Open. 2022.
PMID: 34953399
Free PMC article.